June 29, 2017 / 8:21 PM / 25 days ago

BRIEF-Acorda submits new drug application to U.S. Food And Drug Administration

1 Min Read

June 29 (Reuters) - Acorda Therapeutics Inc:

* Acorda submits new drug application to U.S. Food And Drug Administration for inbrijatm (CVT-301, levodopa inhalation powder)

* Acorda Therapeutics Inc - trade name for CVT-301, inbrija, has been conditionally accepted by FDA

* Acorda Therapeutics Inc - co anticipates FDA to inform acorda by end of September if submission has been deemed complete and permits a full review

* Acorda Therapeutics Inc - plans to file a marketing authorization application (MAA) in EUROPE for CVT-301 by end of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below